ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2006
Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia.The Cochrane database of systematic reviews · 2011Pooled it
- A State of the Art Review on the Recalcitrant Candidiasis as a Clue of Inborn Errors of Immunity in Newborns.Journal of immunology research · 2026Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Interplay between fungal infections and autoimmunity: mechanisms and therapeutic perspectives.EMBO molecular medicine · 2025Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Antifungal chemotherapies and immunotherapies for the future.Parasite immunology · 2023Review
- Review
- Neutropenia and Infection Prophylaxis in Childhood Cancer.Current oncology reports · 2022Review
- New insights on mucormycosis and its association with the COVID-19 pandemic.Future science OA · 2022Review
- COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.3 Biotech · 2022Review
- Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.Frontiers in cellular and infection microbiology · 2020Review
- Granulocyte transfusions: A concise review for practitioners.Cytotherapy · 2017Review
- Changing Trends in the Use of Granulocyte Transfusions in Neutropenic Children with Sepsis in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Methods of Controlling Invasive Fungal Infections Using CD8Frontiers in immunology · 2017Review
- Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies.Journal of translational medicine · 2015Review
- Human Fungal Pathogens of Mucorales and Entomophthorales.Cold Spring Harbor perspectives in medicine · 2014Review
- Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Article
- Pulmonary mucormycosis: what is the best strategy for therapy?Respiratory care · 2013Article
- Th17 cells in immunity to Candida albicans.Cell host & microbe · 2012Review
- Recent advances in the treatment of mucormycosis.Current infectious disease reports · 2010Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections represent a life-threatening complication for patients receiving chemotherapy or undergoing hematopoietic stem cell transplantation. Historically, antifungal monotherapy is associated with a poor outcome. We treated three children with hematological malignancies and proven fungal infections (one cerebral mold infection, one disseminated Candida infection, one naso-pharyngeal mucor infection) with combination antifungal therapy plus granulocyte-colony-stimulation-factor-mobilized granulocyte transfusions as secondary prophylaxis during subsequent neutropenic episodes. With this approach, the fungal infection was effectively treated, and the anticancer therapy was completed without major delay. All children survived the fungal infection and the underlying malignancy. These experiences illustrate the feasibility of this approach using more than one antifungal agent together with immune-therapy in high-risk patients.
Indexed as
Identifiers
16482446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.